SUBSTANTIAL EXTERNAL DOSE RATE VARIABILITY OBSERVED IN A COHORT OF LU-177 PATIENTS INDEPENDENT OF BMI AND SEX

Author:

Bellamy Michael1ORCID,Chu Bae1,Serencsits Brian1ORCID,Quinn Brian1ORCID,Prasad K1,Altamirano J1,Williamson Matthew1,Miodownik Daniel1,Abrahams Natalie2,Chen Fanny1,Bierman David1,Wutkowski M1,Dauer Lawrence1

Affiliation:

1. Department of Medical Physics, Memorial Sloan Kettering , 1275 York Avenue, New York, NY 10065 , USA

2. Siena College , 515 Loudon Road, Loudonville, New York, NY 12211 , USA

Abstract

Abstract External dose rates were measured 1 m away from 230 Lu-177 patients to characterise the variability in normalised dose rates as a function of administered activity, body mass index (BMI) and sex. The largest dose rate observed was 0.07 mSv/h associated with an administered activity of 7.2 GBq. Substantial variability was found in the distribution of the normalised dose rate associated that had an average of 0.0037 mSv/h per GBq and a 95% confidence interval of 0.0024–0.0058 mSv/h per GBq. Based on this study, estimating the patient dose rate based on the Lu-177 gamma exposure factor overestimates the dose rate by a factor of 2. A statistically significant inverse relationship was found between the patient dose rate and patient BMI and an empirically derived equation relating these two quantities was reported. On average, male patient dose rates were 3.5% lower than female dose rates, which may be attributed to the larger average BMI of the male patient group.

Funder

National Institutes of Health

National Cancer Institute Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,General Medicine,Radiation,Radiological and Ultrasound Technology

Reference27 articles.

1. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy;Hosono;Ann. Nucl. Med.,2018

2. Therapeutic radiopharmaceuticals;Volkert;Chem. Rev.,1999

3. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors;Claringbold;Cancer Biother. Radiopharm.,2012

4. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103;ICRP

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3